Regeneron Pharmaceuticals Inc (REGN)vsWarner Bros Discovery Inc (WBD)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
WBD
Warner Bros Discovery Inc
$27.22
-0.22%
COMMUNICATION SERVICES · Cap: $67.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Warner Bros Discovery Inc generates 160% more annual revenue ($37.30B vs $14.34B). REGN leads profitability with a 31.4% profit margin vs 1.9%. REGN appears more attractively valued with a PEG of 1.56. REGN earns a higher WallStSmart Score of 58/100 (C).
REGN
Buy58
out of 100
Grade: C
WBD
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Margin of Safety
-106.3%
Fair Value
$13.57
Current Price
$27.22
$13.65 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Large-cap with strong market position
Reasonable price relative to book value
Generating 1.4B in free cash flow
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
2.3% earnings growth
ROE of 2.1% — below average capital efficiency
1.9% margin — thin
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : WBD
The strongest argument for WBD centers on Market Cap, Price/Book, Free Cash Flow.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : WBD
The primary concerns for WBD are EPS Growth, Return on Equity, Profit Margin. A P/E of 94.1x leaves little room for execution misses. Thin 1.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
WBD carries more volatility with a beta of 1.68 — expect wider price swings.
REGN is growing revenue faster at 2.5% — sustainability is the question.
WBD generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (58/100 vs 51/100), backed by strong 31.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Warner Bros Discovery Inc
COMMUNICATION SERVICES · ENTERTAINMENT · USA
Warner Bros. The company is headquartered in New York, New York.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?